Description_x000D_ Application_x000D_ SB-216763 was used to inhibit GSK-3β in human brain microvascular endothelial cell line and colorectal cancer cells._x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ SB-216763 is a small molecule that competes with ATP and potently inhibits the activity α and β isozymes of GSK-3. It acts as neuroprotectant and prevents neuronal cell death induced by PI3-kinase pathway. It also delays preconditioning, reduces infarct size and prevents cardiac ischemia._x000D_ Potent, selective, cell permeable glycogen synthase kinase-3 (GSK-3) inhibitor._x000D_ Features and Benefits_x000D_ This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm._x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound is featured on the GSK-3 and PKB/Akt pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here._x000D_ This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Glaxo­Smith­Kline_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC